| Literature DB >> 28730318 |
Lianne Verbeek1,2, Faiez A Joemmanbaks3, Jacoba M E Quak4, Ram N Sukhai4, Johanna M Middeldorp5, Dick Oepkes5, Enrico Lopriore3.
Abstract
The aim of this study is to investigate the short-term renal function in neonates with twin-twin transfusion syndrome (TTTS), treated with fetoscopic laser surgery (laser group) or conservatively (non-laser group). Creatinine and urea levels and urine output were recorded in the first week after birth. Primary outcome was short-term renal dysfunction, defined as a creatinine level of >100 μmol/L during the first week postpartum. We evaluated 312 twins (laser group, n = 274; non-laser group, n = 38). Median creatinine and urea levels were lower in the laser group than in the non-laser group (71 versus 82 μmol/L, p = 0.002). Short-term renal dysfunction was lower in the laser group compared to the non-laser group (7.2 versus 34.4%, p < 0.001). Within the laser group, creatinine levels were significantly higher in the subgroup with incomplete laser surgery compared to twins with successful laser surgery (76 versus 69 μmol/L, p = 0.018). No differences were found between donors and recipients except for a higher incidence of oliguria in donors in the non-laser group on day 1.Entities:
Keywords: Creatinine; Fetoscopic laser surgery; Monochorionic twins; Renal function; Renal insufficiency; Twin-twin transfusion syndrome
Mesh:
Substances:
Year: 2017 PMID: 28730318 PMCID: PMC5563331 DOI: 10.1007/s00431-017-2964-2
Source DB: PubMed Journal: Eur J Pediatr ISSN: 0340-6199 Impact factor: 3.183
Baseline characteristics in twins affected by TTTS treated with laser surgery (laser group) and treated conservatively (non-laser group)
| Laser group ( | Non-laser group ( | |
|---|---|---|
| TTTS stage at diagnosisb | 2 (1–3)c | 1 (1–3)d |
| TTTS stage 1— | 72 (26.3%)c | 16 (42.1%)d |
| Gestational age at diagnosis—weekb | 19 (17–22)e | 28 (26–29)d |
| Gestational age at birth—weekb | 32 (30–34) | 30 (29–34) |
| Cesarean section—no (%) | 114 (41.6%) | 30 (78.9%) |
| Female—no (%) | 134 (48.9%) | 14 (36.8%) |
| Birth weight—gb | 1652 (1257–2046) | 1548 (1039–2205) |
| Birth weight difference—%b | 10.5 (5.2–20.6) | 9.8 (8.1–21.7) |
aRefers to the number of neonates
bValue given as median (IQR)
c4.4% (12) missing
d26% (10) missing
e3.6% (10) missing
Renal function in the laser group and non-laser group and between the subgroup with complete laser and incomplete laser treatment
| Laser group | ||||||
|---|---|---|---|---|---|---|
| Laser group ( | Non-laser group ( |
| Complete laser ( | Incomplete laser ( |
| |
| Creatinine week 1—μmol/Lb | 71 (61–81)c | 82 (69–148)d | 0.002 | 69 (59–80)e | 76 (66–87)f | 0.018 |
| Creatinine >100 μmol/L— | 12 (7.1%)c | 11 (37.9%)d | <0.001 | 6 (5%)e | 6 (15%)f | 0.073 |
| Urea week 1—mmol/Lb | 5.2 (3.6–7.1)g | 7.6 (5.8–11.5)d | <0.001 | 5.1 (3.6–7.1)h | 6.2 (4.4–7.2)f | 0.178 |
| UO day 1 <1 ml/kg/h— | 69 (40.6%)i | 14 (60.9%)j | 0.075 | 55 (42%)k | 14 (37%)l | 0.708 |
| UO day 2 <1 ml/kg/h— | 8 (4.8%)m | 9 (36.0%)n | <0.001 | 5 (4%)e | 3 (8%)l | 0.387 |
| UO day 3 <1 ml/kg/h— | 4 (2.6%)o | 2 (8.3%)p | 0.192 | 2 (2%)q | 2 (5%)r | 0.252 |
| MBP at birth—mmHgb | 37 (33–43)s | 39 (32–52)t | 0.349 | 37 (33–42)u | 39 (33–45) | 0.247 |
| Heartrate at birth—bpmb | 154 (143–166)v | 146 (131–158)t | 0.004 | 154 (142–166)w | 156 (149–164) | 0.298 |
UO urine output, MBP mean blood pressure, bpm beats per minute
aRefers to the number of neonates
bValue given as median (IQR)
c38.6% (106) missing
d23.7% (9) missing
e0.8% (1) missing
f10.8% (5) missing
g1.8% (5) missing
h43.9% (100) missing
i38.0% (104) missing
j39.5% (15) missing
k42.1% (96) missing
l17.4% (8) missing
m39.8% (109) missing
n34.2% (13) missing
o48.5% (133) missing
p36.8% (14) missing
q50% (114) missing
r19.6% (9) missing
s19.3% (53) missing
t13.2% (5) missing
u23.2% (53) missing
v13.1% (36) missing
w15.8% (36) missing
Clinical outcome in TTTS twins in the laser group and the non-laser group
| Laser group ( | Non-laser group ( |
| |
|---|---|---|---|
| Hypotension— | 12 (4.5%)b | 8 (21.1%) | 0.001 |
| Cerebral injury— | 8 (2.9%) | 1 (2.7%)c | 1.000 |
| Necrotizing enterocolitis— | 3 (1.1%)g | 1 (2.6%) | 0.408 |
| Patent ductus arteriosus— | 37 (13.5%) | 10 (26.3%) | 0.051 |
| Sepsis— | 25 (9.1%) | 5 (13.5%)c | 0.377 |
| Fetal distress— | 1 (0.4%)d | 4 (11.1%)e | 0.001 |
| Mortality— | 8 (2.9%) | 5 (13.2%) | 0.013 |
aRefers to the number of neonates
b2.2% (6) missing
c2.6% (1) missing
d0.4% (1) missing
e5.3% (2) missing
|
|
|
|